Suven Life obtains patents for products from Israel and Japan

Suven Life Sciences announced Tuesday that it has obtained a product patent, respectively for Israel and Japan, for a new chemical entity (NCE) used in the treatment of disorders badociated with neurodegenerative diseases.

2036 and 2034 respectively, the company said in a document on BSE.

"We welcome the issuance of these patents to Suven for our portfolio of molecules in the CNS system, currently being developed for cognitive disorders characterized by high unmet medical needs and potential. huge in the global market, "Venkat Jasti, general manager of Suven Life, said

that patent claims are being developed as therapeutic agents useful in the treatment of cognitive disorders badociated with neurodegenerative disorders such as the disease Alzheimer's, attention-deficit hyperactivity disorder (ADHD), Huntington's disease, Huntington's disease, he adds.

The shares of Suven Life Sciences are trading 0.56% up, at 242.10 rupees on BSE.

(This story was not modified by Business Standard staff and is generated automatically from a syndicated thread.)